Abstract
BackgroundIt is unclear whether simultaneous primary neoplasm resection and immunotherapy for advanced lung cancer is safe. We report a case of an elderly man with advanced lung cancer and myxofibrosarcoma.Case presentationThe advanced lung cancer was treated with pembrolizumab, and partial response was achieved in 3 months. However, the mediastinal cyst enlarged rapidly. We resected the mediastinal tumor and diagnosed it as myxofibrosarcoma. The postoperative course was uneventful. Immunotherapy was resumed after the operation without any adverse effects. No recurrence of mediastinal sarcoma or progression of lung cancer was found until the patient died in an accident 8 months after surgery.ConclusionSurgery for mediastinal sarcoma could be performed safely in combination with immunotherapy for advanced lung cancer.
Highlights
It is unclear whether simultaneous primary neoplasm resection and immunotherapy for advanced lung cancer is safe
Immune checkpoint inhibitors can have great efficacy in some advanced nonsmall cell lung cancers (NSCLCs), but cause unique immune-related adverse effects [1]. It is unclear whether simultaneous primary neoplasm resection combined with immunotherapy is safe. This is the first report on the combination of immunotherapy for advanced Non-small cell lung cancer (NSCLC) and surgery for mediastinal sarcoma
We determined that the patient had double neoplasms with advanced NSCLC and a mediastinal tumor
Summary
It is unclear whether simultaneous primary neoplasm resection and immunotherapy for advanced lung cancer is safe. Immune checkpoint inhibitors can have great efficacy in some advanced nonsmall cell lung cancers (NSCLCs), but cause unique immune-related adverse effects [1]. This is the first report on the combination of immunotherapy for advanced NSCLC and surgery for mediastinal sarcoma. We determined that the patient had double neoplasms with advanced NSCLC and a mediastinal tumor.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
